Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Synact Pharma Aps has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's current prosecution activity is focused, involving 1 distinct examiner and 1 distinct art unit. This suggests that the company's active applications are being reviewed within a single specialized technical group. Such concentration allows for a more unified approach to patent prosecution, as the technical review is not fragmented across different departments.
The busiest examiner for the portfolio is RAO, PADMAJA S, who is managing 1 busiest examiner pending office action. This single action constitutes the total of 1 pending office action for the company. With only 1 distinct art unit involved, the company's current patent office interactions are entirely handled by this specific examiner. This alignment allows the applicant to focus their legal and technical arguments on the specific concerns of 1 distinct examiner, which can lead to more predictable outcomes within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17119142 | TREATMENT OF PROTEINURIA | RAO, PADMAJA S | 37d overdue |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17119142 | TREATMENT OF PROTEINURIA | RAO, PADMAJA S | 1627 | DP | Non-Final OA | 37d overdue | Pending | Dec 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial